Keros Therapeutics(KROS)
Focus: Keros Therapeutics is a publicly traded biotech company focused on rare muscle disorders and rare diseases, with a pipeline of early-stage assets in Phase 2 development.
Profile data last refreshed 13h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
21+33 this month
Hot — 41 jobs added in 30d
Net +33 (41 new, 8 removed). Aggressive expansion phase.
Should You Work at Keros Therapeutics?
AI assessmentA high-risk, high-impact opportunity best suited for researchers and clinical developers motivated by rare disease science and willing to accept pre-commercial execution risk and equity volatility.
Why Work Here
- Rare disease focus offers deep scientific impact and unmet medical need in specialized areas like Duchenne Muscular Dystrophy and pulmonary arterial hypertension.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
KER-047
Iron Deficiency AnemiaClinical Trials (1)
NCT05927012A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
Phase 2Help build intelligence for Keros Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.